Clinical trials: Hepatic Neoplasm

Hepatocellular Carcinoma

SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

• Completed
• Age: 18 years and older
• Phase 2
• Results posted

A Phase 2 open-label, single-arm, non-randomized study in the treatment of advanced hepatocellular carcinoma (HCC) patients who failed prior treatment with sorafenib using a Simon's 2-stage design.

Trial name

NCT01752933

Testing

SGI-110

Where

24 sites in United States, Canada and 1 more

Volunteers

52 people

Sponsor

Astex Pharmaceuticals, Inc.